ART-AD Study
A new approach to dementia treatment- targeting the proteins connected to memory loss.

Study at a Glance
Estimated Time Commitment
8 visits over 6-7 monthsEligibility
Ages 50 to 80 yearsDiagnosis Required
Alzheimer's diseaseDiseases Being Studied
Alzheimer's diseaseOverview
Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B.
Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.
Over the course of this trial, we will measure the success of the drug in preventing further neurodegeneration.
Eligibility
Qualifications to participate include, but are not limited to:
- Adults ages 50-80 years
- Clinical diagnosis of early Alzheimer’s disease
- Have a reliable informant or caregiver
If participants are taking Alzheimer’s medications, they must be on a stable dose for at least 8 weeks before first screening visit.
Non-eligibility
Disqualifications to participate include, but are not limited to:
-
- Patients taking memantine medication
Process
Treatment will include 8 study visits over 6-7 months.
The 6-7 months will include 30 days of pre-treatment, a 24-week treatment period and a follow up visit one month following treatment.
Pre-treatment visits include:
-
-
- Comprehensive neuropsychological exams
- Tablet-based neuropsychological exams
- Lumbar puncture to collect cerebrospinal fluid
- Blood draw
-
During treatment, visits include:
-
-
- Review of medication
- Physical examinations
- Brief cognitive screenings
- Blood draw
-
The post-treatment visit one month after the final dose of medication includes a:
-
- Comprehensive neuropsychological exam
- Lumbar puncture to collect cerebrospinal fluid
- Blood draw
- Disenrollment
Meet Your Clinical Research Team
Contact us
Barshop Institute for Aging and Longevity
210-450-3333